TEMENOS
Temenos (SIX: TEMN), the banking software company, has been listed as the only ‘Global Power Seller’ in Forrester’s prestigious Global Banking Platform Deals Survey 2021 , with a 20% increase in new named deals compared to previous year. Temenos was the only top 5 vendor to grow its number of deals in 2020. Temenos landed more new global banking deals than any other surveyed provider in 2020, as stated in the Forrester report. Temenos was also named a ‘Top Global Player’ in the survey, based on combined deals, which represent a vendor’s ability to enhance its market position and keep creating value for its existing customers. Temenos also became the first vendor to be recognized by Forrester as a ‘Top Global Cross-Seller’ in Forrester’s newest category focused on extended business. According to Forrester, “extended business deals represent a vendor’s ability to keep creating value for its existing customers.”
Forrester reconfirmed Temenos’ status as a ‘Top Global Player’ for the 9th consecutive year. This ranking recognizes platforms with over 150 combined deals (new names and extended deals with existing customers) in more than five regions. With 209 deals signed with new and existing customers, Temenos maintained its position. Temenos also retains its position as a ‘Global Power Seller’, the highest status in the vendor pyramid for new deals, with 93 new business deals in 2020, 3X more deals than the next surveyed vendor. This marks the 15th consecutive year that Temenos has received this recognition.
Max Chuard, Chief Executive Officer, Temenos, said: “We are delighted to be recognized in Forrester’s Global Banking Platform Deals Survey across all seven surveyed regions and categories, and to be the only technology company to be in the top segment of all three tables. We operate in a huge USD 63 billion addressable market, which is largely underpenetrated, with only 27% today spent with third-parties, which creates big opportunities. As the deal figures show, Temenos is one of the only technology providers continuing to grow. We have over 3,000 customers, including over 70 challengers, and we are servicing them by constantly investing in innovation and in our technology roadmap across products and geographies to help them transform their IT landscapes. And by bringing to market The Temenos Banking Cloud, we now empower banks to digitally transform and massively scale faster than ever. We are putting banks in control of their business models and innovation cycles, giving them the agility and speed to deliver real value to their customers and build profitable businesses.”
The report, Use The Pandemic's Market Impact To Improve The ROI Of Digital Transformation:
Results From Forrester's Global Banking Platform Deals Survey 2021 , authored by Jost Hoppermann, Vice President and Principal Analyst, Forrester, states: “Banks have long recognized that their application landscapes can’t deliver the seamless and convenient experiences their customers require, leading to many institutions accepting the transformation imperative[...]. The pandemic has improved the banking industry’s application landscapes and digital readiness. However, it is still far from perfect: Despite the increased transformation pace, plenty of functional areas still need digital transformation. Well-suited off-the-shelf banking software is an effective option to drive this transformation.”
Temenos was most recently recognized as a leader in ‘The Forrester Wave : Digital Banking Processing Platforms, Q3 2020’ (Retail Banking and Corporate Banking ) and previously in ‘The Forrester Wave™: Digital Banking Engagement Platforms, Q3 2019 ’.
The Global Banking Platform Deals Survey 2021 is an independent survey conducted annually by Forrester. It assesses both the volume and geographical spread of banking platform sales to new and existing customers for 2020 deals. The research is used by decision-makers at financial institutions around the world looking to effectively evaluate the plethora of banking software solutions available.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210606005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom